These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23250712)

  • 1. Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.
    Nakajima K; Chiba K; Tsubamoto H; Walsh J; Strawn L; Suwa T
    Invest New Drugs; 2013 Aug; 31(4):1051-5. PubMed ID: 23250712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
    Hirai T; Suzuki A; Yamori T; Matsuura M
    Invest New Drugs; 2022 Feb; 40(1):142-150. PubMed ID: 34417913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan.
    Tanaka M; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Mar; 53(2):199-206. PubMed ID: 29732928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
    Tajima G; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds.
    DiMasi JA; Hermann JC; Twyman K; Kondru RK; Stergiopoulos S; Getz KA; Rackoff W
    Clin Pharmacol Ther; 2015 Nov; 98(5):506-13. PubMed ID: 26239772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.
    Sato M; Ochiai Y; Kijima S; Nagai N; Ando Y; Shikano M; Nomura Y
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):413-415. PubMed ID: 28568566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PMDA's Initiatives to Encourage the New Drug Development for Rare Cancers].
    Takahashi H; Yaginuma H
    Gan To Kagaku Ryoho; 2023 Nov; 50(11):1155-1159. PubMed ID: 38056865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
    Nakayama H; Tsukamoto K
    Invest New Drugs; 2018 Aug; 36(4):702-708. PubMed ID: 29667133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.